FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Roberto Labianca

Research Profile

Procedures

Chemicals & Drugs

Disorders

Concepts & Ideas

Geographic Areas

Italy

Physiology

Disease Progression

Co-author Network

Publications

TOP 3
Dino Amadori; Thomas Bauknecht; Eva Carrasco; Durisala Desaiah; Roberto Labianca; Valerie Moreau; Siegfried Roesel; Victoria Soldatenkova; Beatrice Uziely; Miguel Martin
A randomized phase II non-comparative study of pemetrexed‑carboplatin and gemcitabine‑vinorelbine in anthracycline- and taxane-pretreated advanced breast cancer patients.
Frank A Sinicrope; Greg Yothers; Al Benson; Aimery Degramont; Nathan R Foster; Richard M Goldberg; Roberto Labianca; Michael J O'Connell; Daniel J Sargent; Jean Francois Seitz
Body mass index at diagnosis and survival among colon cancer patients enrolled in clinical trials of adjuvant chemotherapy.
Andrea Ardizzoni; Fausto Barbieri; Corrado Boni; Luca Boni; Sebastiano Buti; Mara A Cafferata; Andrea Camerini; Roberta Camisa; Libero Ciuffreda; Ida Colantonio; Lucio Crinò; Filippo de Marinis; Francesco Di Costanzo; Giovenzio Genestreti; Roberto Labianca; Rodolfo Mattioli; Rodolfo Passalacqua; Antonio Pazzola; Antonio Santo; Carmelo Tibaldi; Marcello Tiseo; Andrew D Vincent; Nicoletta Zilembo; Domenico Amoroso; Egbert F Smit
Pemetrexed versus pemetrexed and carboplatin as second-line chemotherapy in advanced non-small-cell lung cancer: results of the GOIRC 02-2006 randomized phase II study and pooled analysis with the NVALT7 trial.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Roberto Labianca (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Dino Amadori; Thomas Bauknecht; Eva Carrasco; Durisala Desaiah; Roberto Labianca; Valerie Moreau; Siegfried Roesel; Victoria Soldatenkova; Beatrice Uziely; Miguel Martin
A randomized phase II non-comparative study of pemetrexed‑carboplatin and gemcitabine‑vinorelbine in anthracycline- and taxane-pretreated advanced breast cancer patients.
International journal of oncology 2013;42(5):1778-85.
2013: Frank A Sinicrope; Greg Yothers; Al Benson; Aimery Degramont; Nathan R Foster; Richard M Goldberg; Roberto Labianca; Michael J O'Connell; Daniel J Sargent; Jean Francois Seitz
Body mass index at diagnosis and survival among colon cancer patients enrolled in clinical trials of adjuvant chemotherapy.
Cancer 2013;119(8):1528-36.
2012: Andrea Ardizzoni; Fausto Barbieri; Corrado Boni; Luca Boni; Sebastiano Buti; Mara A Cafferata; Andrea Camerini; Roberta Camisa; Libero Ciuffreda; Ida Colantonio; Lucio Crinò; Filippo de Marinis; Francesco Di Costanzo; Giovenzio Genestreti; Roberto Labianca; Rodolfo Mattioli; Rodolfo Passalacqua; Antonio Pazzola; Antonio Santo; Carmelo Tibaldi; Marcello Tiseo; Andrew D Vincent; Nicoletta Zilembo; Domenico Amoroso; Egbert F Smit
Pemetrexed versus pemetrexed and carboplatin as second-line chemotherapy in advanced non-small-cell lung cancer: results of the GOIRC 02-2006 randomized phase II study and pooled analysis with the NVALT7 trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30(36):4501-7.
2012: Arnaud D Roth; Sabine Tejpar; Pu Yan; Fred Bosman; Laura Cisar; David Cunningham; Giovanni d'Ario; Mauro Delorenzi; Roberto Fiocca; Dirk Klingbiel; Roberto Labianca; Bernard Nordlinger; Eric Van Cutsem
Integrated analysis of molecular and clinical prognostic factors in stage II/III colon cancer.
Journal of the National Cancer Institute 2012;104(21):1635-46.
2012: Francesco Perrone; Filippo de Braud; Roberto Labianca; Carlo Tomino; Fausto Roila
Tackling off-label use of anticancer drugs.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30(22):2800; author reply 2801.
2012: Joleen Hubbard; Roberto Labianca; Michael J O'Connell; Charles Blanke; Archie Bleyer; Aimery de Gramont; Erin Green; Qian Shi; David M Thomas; Greg Yothers; Daniel Sargent
Benefits and adverse events in younger versus older patients receiving adjuvant chemotherapy for colon cancer: findings from the Adjuvant Colon Cancer Endpoints data set.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30(19):2334-9.
2012: Alberto Zaniboni; Giuseppe Valmadre; Enzo Veltri; Enrico Aitini; Sandro Barni; Stefano Cascinu; Vincenzo Catalano; Claudio Codignola; Domenica Ferrara; Daris Ferrari; Roberto Labianca
FOLFIRI as second-line chemotherapy for advanced pancreatic cancer: a GISCAD multicenter phase II study.
Cancer chemotherapy and pharmacology 2012;69(6):1641-5.
2012: Melina Verso; Giancarlo Agnelli; Sandro Barni; Giampietro Gasparini; Roberto Labianca
A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: the Protecht score.
Internal and emergency medicine 2012;7(3):291-2.
2012: Augusto Caraceni; Franco De Conno; Roberto Labianca; Luigi Lanata; Marco Maltoni; Sebastiano Mercadante; Giustino Varrassi; Giovanni Zaninetta; Furio Zucco; Michela Bagnasco; Oscar Bertetto
Episodic (breakthrough) pain prevalence in a population of cancer pain patients. Comparison of clinical diagnoses with the QUDEI--Italian questionnaire for intense episodic pain.
Journal of pain and symptom management 2012;43(5):833-41.
2012: Roberto Labianca; Piercarlo Sarzi Puttini; Renato Vellucci; Stefano Maria Zuccaro; Paolo Cherubino; Diego Fornasari
Adverse effects associated with non-opioid and opioid treatment in patients with chronic pain.
Clinical drug investigation 2012;32 Suppl 1():53-63.
2012: Paolo Cherubino; Piercarlo Sarzi Puttini; Stefano Maria Zuccaro; Roberto Labianca
The management of chronic pain in important patient subgroups.
Clinical drug investigation 2012;32 Suppl 1():35-44.
2012: Piercarlo Sarzi Puttini; Renato Vellucci; Stefano Maria Zuccaro; Paolo Cherubino; Roberto Labianca; Diego Fornasari
The appropriate treatment of chronic pain.
Clinical drug investigation 2012;32 Suppl 1():21-33.
2012: Stefano Maria Zuccaro; Paolo Cherubino; Roberto Labianca; Piercarlo Sarzi Puttini; Renato Vellucci; Diego Fornasari
Barriers to pain management: focus on opioid therapy.
Clinical drug investigation 2012;32 Suppl 1():11-9.
2012: C Boni; L Boni; Mara Argenide Cafferata; C Caroti; F Di Costanzo; D Germano; F Grossi; Roberto Labianca; G Marini; E Matano; M Mencoboni; C Pennucci; Tiziana Prochilo; F Recchia; Marcello Tiseo; F Zanelli; A Ardizzoni; A Bagnulo; E Baldini; C Barone
Triplets versus doublets, with or without cisplatin, in the first-line treatment of stage IIIB-IV non-small cell lung cancer (NSCLC) patients: a multicenter randomised factorial trial (FAST).
British journal of cancer 2012;106(4):658-65.
2012: Roberto Labianca; Piercarlo Sarzi Puttini; Renato Vellucci; Stefano Maria Zuccaro; Paolo Cherubino; Diego Fornasari
Adverse effects associated with non-opioid and opioid treatment in patients with chronic pain.
Clinical drug investigation 2012;32 Suppl 1():53-63.
2012: Paolo Cherubino; Piercarlo Sarzi Puttini; Stefano Maria Zuccaro; Roberto Labianca
The management of chronic pain in important patient subgroups.
Clinical drug investigation 2012;32 Suppl 1():35-44.
2012: Stefano Maria Zuccaro; Paolo Cherubino; Roberto Labianca; Piercarlo Sarzi Puttini; Renato Vellucci; Diego Fornasari
Barriers to pain management : focus on opioid therapy.
Clinical drug investigation 2012;32 Suppl 1():11-9.
2011: Tommaso De Pas; Monica Giovannini; Roberto Labianca; Michela Manzotti; Lorenzo Spaggiari; Francesca Toffalorio; Giuseppe Trifirò; Chiara Catania; Massimo Barberis
Large-cell neuroendocrine carcinoma of the lung harboring EGFR mutation and responding to gefitinib.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(34):e819-22.
2011: Stefano Cascinu; Francesco Ferraù; Eva Galizia; Roberto Labianca; Gabriele Luppi; Francesca Pucci; Rossana Berardi; Giordano Domenico Beretta; Rosa Rita Silva; MARIO SCARTOZZI
Pegylated liposomal doxorubicin, 5-fluorouracil and cisplatin versus mitomycin-C, 5-fluorouracil and cisplatin for advanced gastric cancer: a randomized phase II trial.
Cancer chemotherapy and pharmacology 2011;68(1):37-43.
2011: Frank A Sinicrope; Stephen N Thibodeau; Greg Yothers; George P Kim; Carmen Allegra; Nathan R Foster; Steven Gallinger; Roberto Labianca; Silvia Marsoni; Genevieve Monges; Malcolm J Moore; Daniel J Sargent
DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy.
Journal of the National Cancer Institute 2011;103(11):863-75.
2011: Eric Van Cutsem; C Van de Velde; N Arber; Y Bang; A Benson; A Cervantes; E Diaz-Rubio; Mario Dicato; M Ducreux; R Geva; R Glynne-Jones; A Grothey; D Haller; Karin Haustermans; Y K Kang; D Kerr; Roberto Labianca; Florian Lordick; J Marshall; B Minsky; Bernard Nordlinger; A Ohtsu; N Pavlidis; A Roth; Philippe Rougier; HJ Schmoll; Alberto Sobrero; Josep Tabernero; J Zalcberg
The diagnosis and management of gastric cancer: expert discussion and recommendations from the 12th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2010.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2011;22 Suppl 5():v1-9.
2011: MARIO SCARTOZZI; Italo Bearzi; Alessandra Mandolesi; R Giampieri; L Faloppi; Eva Galizia; Fotios Loupakis; alberto zaniboni; Fausto Zorzi; T Biscotti; Roberto Labianca; Alfredo Falcone; Stefano Cascinu
Epidermal growth factor receptor (EGFR) gene promoter methylation and cetuximab treatment in colorectal cancer patients.
British journal of cancer 2011;104(11):1786-90.
2011: Gabriella Farina; Flavia Longo; Olga Martelli; Ida Pavese; Andrea Mancuso; Luca Moscetti; Roberto Labianca; Alessandro Bertolini; Enrico Cortesi; Antonio Farris; Daniele Fagnani; Maria Cristina Locatelli; Giuseppe Valmadre; Antonio Ardizzoia; Maurizio Tomirotti; Eliana Rulli; Marina Chiara Garassino; Alberto Scanni
Rationale for treatment and study design of tailor: a randomized phase III trial of second-line erlotinib versus docetaxel in the treatment of patients affected by advanced non-small-cell lung cancer with the absence of epidermal growth factor receptor mutations.
Clinical lung cancer 2011;12(2):138-41.
2011: mario mandala; Gian Lorenzo Imberti; Dario Piazzalunga; Maurizio Belfiglio; Giuseppe Lucisano; Roberto Labianca; Lorenzo Marchesi; Barbara Merelli; Silvana Robone; Paola Poletti; Laura Milesi; Carlo Tondini
Association of socioeconomic status with Breslow thickness and disease-free and overall survival in stage I-II primary cutaneous melanoma.
Mayo Clinic proceedings. Mayo Clinic 2011;86(2):113-9.
2011: Sandro Barni; Carlo Bianchini; Erminio Bonizzoni; Matteo Brighenti; Roberto Labianca; mario mandala; Tania Perrone; Fausto Petrelli; Melina Verso; Giancarlo Agnelli; Giampietro Gasparini
Chemotherapy-associated thromboembolic risk in cancer outpatients and effect of nadroparin thromboprophylaxis: results of a retrospective analysis of the PROTECHT study.
Journal of translational medicine 2011;9():179.
2010: Domenico Alvaro; Renato Cannizzaro; Roberto Labianca; Francesca Valvo; Fabio Farinati
Cholangiocarcinoma: A position paper by the Italian Society of Gastroenterology (SIGE), the Italian Association of Hospital Gastroenterology (AIGO), the Italian Association of Medical Oncology (AIOM) and the Italian Association of Oncological Radiotherapy (AIRO).
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 2010;42(12):831-8.
2010: Roberto Labianca; Barbara Merelli
Screening and diagnosis for colorectal cancer: present and future.
Tumori 2010;96(6):889-901.
2010: Daniel J Sargent; Silvia Marsoni; Genevieve Monges; Stephen N Thibodeau; Roberto Labianca; Stanley R Hamilton; Amy J French; Brian Kabat; Nathan R Foster; Valter Torri; Christine Ribic; Axel Grothey; Malcolm Moore; alberto zaniboni; Jean-Francois Seitz; Frank Sinicrope; Steven Gallinger
Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(20):3219-26.
2010: Eric Van Cutsem; Mario Dicato; N Arber; J Berlin; A Cervantes; Fortunato Ciardiello; A De Gramont; E Diaz-Rubio; M Ducreux; R Geva; Bengt Glimelius; R Glynne Jones; A Grothey; T Gruenberger; D Haller; Karin Haustermans; Roberto Labianca; H J Lenz; B Minsky; Bernard Nordlinger; A Ohtsu; N Pavlidis; Philippe Rougier; W Schmiegel; C Van de Velde; HJ Schmoll; Alberto Sobrero; Josep Tabernero
Molecular markers and biological targeted therapies in metastatic colorectal cancer: expert opinion and recommendations derived from the 11th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2009.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2010;21 Suppl 6():vi1-10.
2010: Roberto Labianca; B Nordlinger; Giordano D Beretta; A Brouquet; A Cervantes
Primary colon cancer: ESMO Clinical Practice Guidelines for diagnosis, adjuvant treatment and follow-up.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2010;21 Suppl 5():v70-7.
2010: Roberto Labianca; Giordano D Beretta; Basem Kildani; Laura Milesi; Federica Merlin; Stefania Mosconi; M Adelaide Pessi; Tiziana Prochilo; Antonello Quadri; Gemma Gatta; Filippo de Braud; Jacques Wils
Colon cancer.
Critical reviews in oncology/hematology 2010;74(2):106-33.
2010: Mario Mandalà; Roberto Labianca
Venous thromboembolism (VTE) in cancer patients. ESMO clinical recommendations for prevention and management.
Thrombosis research 2010;125 Suppl 2():S117-9.
2010: Giuseppe Colucci; Roberto Labianca; Francesco Di Costanzo; Vittorio Gebbia; Giacomo Cartenì; Bruno Massidda; Elisa Dapretto; Luigi Manzione; Elena Piazza; Mirella Sannicolò; Marco Ciaparrone; Luigi Cavanna; Francesco Giuliani; Evaristo Maiello; Antonio Testa; Paolo Pederzoli; Massimo Falconi; Ciro Gallo; Massimo Di Maio; Francesco Perrone
Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(10):1645-51.
2010: Rodolfo Passalacqua; Carlo Buzio; Sebastiano Buti; Camillo Porta; Roberto Labianca; Debora Pezzuolo; Roberta Camisa; Roberto Sabbatini; Luigi Benecchi; Caterina Messina; Rita Cengarle; Augusto Vaglio; Matteo Dalla Chiesa; Gianluca Tomasello; Caterina Caminiti
Phase III, randomised, multicentre trial of maintenance immunotherapy with low-dose interleukin-2 and interferon-alpha for metastatic renal cell cancer.
Cancer immunology, immunotherapy : CII 2010;59(4):553-61.
2010: Arnaud D Roth; Sabine Tejpar; Mauro Delorenzi; Pu Yan; Roberto Fiocca; Dirk Klingbiel; Daniel Dietrich; Bart Biesmans; György Bodoky; Carlo Barone; Enrique Aranda; Bernard Nordlinger; Laura Cisar; Roberto Labianca; D Cunningham; Eric Van Cutsem; Fred Bosman
Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(3):466-74.
2010: Flavio Gaspari; Paolo Cravedi; mario mandala; Norberto Perico; Felipe Rodríguez de Leon; Nadia Stucchi; Silvia Ferrari; Roberto Labianca; Giuseppe Remuzzi; Piero Ruggenenti
Predicting cisplatin-induced acute kidney injury by urinary neutrophil gelatinase-associated lipocalin excretion: a pilot prospective case-control study.
Nephron. Clinical practice 2010;115(2):c154-60.
2009: MARIO SCARTOZZI; Italo Bearzi; Alessandra Mandolesi; Eva Galizia; Chiara Pierantoni; Fotios Loupakis; Rossana Berardi; alberto zaniboni; Antonello Quadri; Fausto Zorzi; Simona Biagetti; Cristian Loretelli; Tommasina Biscotti; Roberto Labianca; Gianluca Masi; Alfredo Falcone; Stefano Cascinu
Epidermal growth factor receptor gene promoter methylation in primary colorectal tumors and corresponding metastatic sites: a new perspective for an "old" therapeutic target.
Analytical and quantitative cytology and histology / the International Academy of Cytology [and] American Society of Cytology 2009;31(6):417-23.
2009: Fausto Roila; Enzo Ballatori; Roberto Labianca; Filippo de Braud; Karen Borgonovo; Olga Martelli; Ciro Gallo; Angelo Tinazzi; Francesco Perrone
Off-label prescription of antineoplastic drugs: an Italian prospective, observational, multicenter survey.
Tumori 2009;95(6):647-51.
2009: Giovanni Apolone; Oscar Corli; Emanuele Negri; Simone Mangano; MAURO MONTANARI; Maria Teresa Greco; giovanni Apolone; Oscar Bertetto; Augusto Caraceni; Oscar Corli; Franco De Conno; Roberto Labianca; Marco Maltoni; Flavia Nicora Maria; Valter Torri; Furio Zucco
Effects of transdermal buprenorphine on patients-reported outcomes in cancer patients: results from the Cancer Pain Outcome Research (CPOR) Study Group.
The Clinical journal of pain 2009;25(8):671-82.
2009: Giancarlo Agnelli; Gualberto Gussoni; Carlo Bianchini; Melina Verso; mario mandala; Luigi Cavanna; Sandro Barni; Roberto Labianca; Franco Buzzi; Giovanni Scambia; Rodolfo Passalacqua; Sergio Ricci; Giampietro Gasparini; Vito Lorusso; Erminio Bonizzoni; Maurizio Tonato
Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study.
The lancet oncology 2009;10(10):943-9.
2009: Vincenzo Catalano; Roberto Labianca; Giordano D Beretta; Gemma Gatta; Filippo de Braud; Eric Van Cutsem
Gastric cancer.
Critical reviews in oncology/hematology 2009;71(2):127-64.
2009: Eric Van Cutsem; Roberto Labianca; György Bodoky; Carlo Barone; Enrique Aranda; Bernard Nordlinger; Claire Topham; Josep Tabernero; Thierry André; Alberto Sobrero; Enrico Mini; richard greil; Francesco Di Costanzo; Laurence Collette; Laura Cisar; Xiaoxi Zhang; David Khayat; Carsten Bokemeyer; Arnaud D Roth; D Cunningham
Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(19):3117-25.
2009: Maria Giulia Zampino; Roberto Labianca; Giordano D Beretta; Elena Magni; Gemma Gatta; Maria Cristina Leonardi; antonio chiappa; Roberto Biffi; Filippo de Braud; Jacques Wils
Rectal cancer.
Critical reviews in oncology/hematology 2009;70(2):160-82.
2009: Marcello Tiseo; Cesare Gridelli; Stefano Cascinu; Lucio Crinò; Franco Vito Piantedosi; Francesco Grossi; Alba A Brandes; Roberto Labianca; Salvatore Siena; Domenico Amoroso; Ornella Belvedere; Brunello Valentino; alessandra bearz; Paola Venturino; Andrea Ardizzoni
An expanded access program of erlotinib (Tarceva) in patients with advanced non-small cell lung cancer (NSCLC): data report from Italy.
Lung cancer (Amsterdam, Netherlands) 2009;64(2):199-206.
2009: Rodolfo Passalacqua; Caterina Caminiti; Francesco Campione; Francesca Diodati; Renata Todeschini; Giancarlo Bisagni; Roberto Labianca; Matteo Dalla Chiesa; Raffaella Bracci; Marcello Aragona; Fabrizio Artioli; Luigi Cavanna; Alceste Masina; Francesco De Falco; Barbara Marzocchini; Carmelo Iacono; Antonio Contu; Francesco Di Costanzo; Oscar Bertetto; Maria A Annunziata
Prospective, multicenter, randomized trial of a new organizational modality for providing information and support to cancer patients.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(11):1794-9.
2009: Stefania Mosconi; Giordano D Beretta; Roberto Labianca; Maria G Zampino; Gemma Gatta; Volker Heinemann
Cholangiocarcinoma.
Critical reviews in oncology/hematology 2009;69(3):259-70.
2009: Daniel Sargent; Alberto Sobrero; Axel Grothey; Michael J O'Connell; Marc Buyse; Thierry Andre; Yan Zheng; Erin Green; Roberto Labianca; Chris O'Callaghan; Jean Francois Seitz; Guido Francini; Daniel Haller; Greg Yothers; Richard M Goldberg; Aimery de Gramont
Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(6):872-7.
2009: MARIO SCARTOZZI; Italo Bearzi; Alessandra Mandolesi; Chiara Pierantoni; Fotios Loupakis; alberto zaniboni; Francesca Negri; Antonello Quadri; Fausto Zorzi; Eva Galizia; Rossana Berardi; Tommasina Biscotti; Roberto Labianca; Gianluca Masi; Alfredo Falcone; Stefano Cascinu
Epidermal Growth Factor Receptor (EGFR) gene copy number (GCN) correlates with clinical activity of irinotecan-cetuximab in K-RAS wild-type colorectal cancer: a fluorescence in situ (FISH) and chromogenic in situ hybridization (CISH) analysis.
BMC cancer 2009;9():303.
2008: P Poletti; P Fenaroli; A Milesi; A Paludetti; S Mangiarotti; G Virotta; E Candiago; A Bettini; E R Caremoli; Roberto Labianca; C Tondini
Axillary recurrence in sentinel lymph node-negative breast cancer patients.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2008;19(11):1842-6.
2008: Sebastiano Mercadante; Fausto Roila; Oscar Berretto; Roberto Labianca; Stefania Casilini
Prevalence and treatment of cancer pain in Italian oncological wards centres: a cross-sectional survey.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2008;16(11):1203-11.
2008: Giuseppe Di Lorenzo; William D Figg; Sophie D Fossa; Vincenzo Mirone; Riccardo Autorino; Nicola Longo; Ciro Imbimbo; Sisto Perdonà; Antonio Giordano; Mario Giuliano; Roberto Labianca; Sabino De Placido
Combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: a phase 2 study.
European urology 2008;54(5):1089-94.
2008: Emmanuel Mitry; Anthony L A Fields; Harry Bleiberg; Roberto Labianca; Guillaume Portier; Dongsheng Tu; Donato Nitti; Valter Torri; Dominique Elias; Chris O'Callaghan; Bernard Langer; Giancarlo Martignoni; Olivier Bouché; Franck Lazorthes; Eric Van Cutsem; Laurent Bedenne; Malcolm J Moore; Philippe Rougier
Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(30):4906-11.
2008: Ivan Popov; Alfredo Carrato; Alberto Sobrero; mark vincent; David Kerr; Roberto Labianca; Angelo Raffaele Bianco; Mostafa El-Serafi; Laurent Bedenne; Bernard Paillot; Enrico Mini; Evaristo Sanches; john welch; Laurence Collette; Michel Praet; Jacques Wils
Raltitrexed (Tomudex) versus standard leucovorin-modulated bolus 5-fluorouracil: Results from the randomised phase III Pan-European Trial in Adjuvant Colon Cancer 01 (PETACC-1).
European journal of cancer (Oxford, England : 1990) 2008;44(15):2204-11.
2008: Anna Cecilia Bettini; Carlo Tondini; Paola Poletti; Elena Rota Caremoli; Ugo Guerra; Roberto Labianca
A case of interstitial pneumonitis associated with Guillain-Barré syndrome during administration of adjuvant trastuzumab.
Tumori 2008;94(5):737-41.
2008: Paola Poletti; Anna Cecilia Bettini; Elena Rota Caremoli; Roberto Labianca; Carlo Tondini
Liposomal-encapsulated doxorubicin (Myocet; D-99) and vinorelbine in previously treated metastatic breast cancer patients: a feasibility study.
Tumori 2008;94(5):686-90.
2008: Paul Taylor; Bruno Castagneto; Graham Dark; Maurizio Marangolo; Giorgio V Scagliotti; Rob J van Klaveren; Roberto Labianca; Monika Serke; W Schuette; Jan P van Meerbeeck; David Heigener; Yushan Liu; Susumu Adachi; Johannes Blatter; Joachim von Pawel
Single-agent pemetrexed for chemonaïve and pretreated patients with malignant pleural mesothelioma: results of an International Expanded Access Program.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2008;3(7):764-71.
2008: Paolo Pedrazzoli; Antonio Farris; Salvatore Del Prete; Filomena Del Gaizo; Daris Ferrari; Clara Bianchessi; Giuseppe Colucci; Alberto Desogus; Teresa Gamucci; Alessandro Pappalardo; Giuseppe Fornarini; Paola Pozzi; Alessandra Fabi; Roberto Labianca; Francesco Di Costanzo; Simona Secondino; Enrico Crucitta; Federica Apolloni; Antonio Del Santo; Salvatore Siena
Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(10):1619-25.
2008: Roberto Labianca; Mario Mandalà; Maurizia Clerici
[Clinical role of palonosetron for patients receiving cisplatin-based chemotherapy].
Tumori 2008;94(2):suppl 23-5.
2008: mario mandala; Cecilia Moro; Roberto Labianca
Venous thromboembolism and pancreatic cancer: incidence, pathogenesis and clinical implications.
Onkologie 2008;31(3):129-35.
2008: Stefano Cascinu; Rossana Berardi; Stefania Salvagni; Giordano D Beretta; Vincenzo Catalano; Francesca Pucci; Alberto Sobrero; Pierosandro Tagliaferri; Roberto Labianca; MARIO SCARTOZZI; F Crocicchio; E Mari; Andrea Ardizzoni
A combination of gefitinib and FOLFOX-4 as first-line treatment in advanced colorectal cancer patients. A GISCAD multicentre phase II study including a biological analysis of EGFR overexpression, amplification and NF-kB activation.
British journal of cancer 2008;98(1):71-6.
2008: Francesco Di Costanzo; Roberto Ravasio; Alberto Sobrero; Oscar Bertetto; Orazio Vinante; Gabriele Luppi; Roberto Labianca; Dino Amadori; Carlo Barone; Marco Carlo Merlano; Flavia Longo; Giovanni Mansueto; Lorenzo Antonuzzo; Silvia Gasperoni
Capecitabine versus bolus fluorouracil plus leucovorin (folinic acid) as adjuvant chemotherapy for patients with Dukes' C colon cancer : economic evaluation in an Italian NHS setting.
Clinical drug investigation 2008;28(10):645-55.
2008: Volker Heinemann; Stefan Boeck; Axel Hinke; Roberto Labianca; Christophe Louvet
Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer.
BMC cancer 2008;8():82.
2008: Stefano Cascinu; Rossana Berardi; Roberto Labianca; Salvatore Siena; Alfredo Falcone; Enrico Aitini; Sandro Barni; Francesco Di Costanzo; Elisa Dapretto; Giuseppe Tonini; Chiara Pierantoni; Salvatore Artale; Silvia Rota; Irene Floriani; MARIO SCARTOZZI; alberto zaniboni
Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II trial.
The lancet oncology 2008;9(1):39-44.
2007: Giuseppe Di Lorenzo; Antonio Rea; Chiara Carlomagno; Stefano Pepe; Giovannella Palmieri; Roberto Labianca; Antonio Chirianni; Alfonso De Stefano; Vincenzo Esposito; Sabino De Placido; Vincenzo Montesarchio
Activity and safety of pegylated liposomal doxorubicin, 5-fluorouracil and folinic acid in inoperable hepatocellular carcinoma: a phase II study.
World journal of gastroenterology : WJG 2007;13(48):6553-7.
2007: Roberto Labianca; Laura Milesi; Stefania Mosconi; M Adelaide Pessi; Giordano D Beretta; A Quadri
The role of adjuvant chemotherapy in colon cancer.
Surgical oncology 2007;16 Suppl 1():S93-6.
2007: Ermenegildo Arnoldi; Maria Dieli; Marina Mangia; Roberto Labianca
Metronomic chemotherapy in elderly patients: do risks exceed benefits in some patients?
Tumori 2007;93(6):647.
2007: Daniel J Sargent; Smitha Patiyil; Greg Yothers; Daniel G Haller; Richard Gray; Jacqueline K Benedetti; Marc Buyse; Roberto Labianca; Jean Francois Seitz; Christopher J O'Callaghan; Guido Francini; Axel Grothey; Michael O'Connell; Paul J Catalano; David Kerr; Erin Green; H Samuel Wieand; Richard M Goldberg; Aimery de Gramont
End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(29):4569-74.
2007: mario mandala; Michele Reni; Stefano Cascinu; S Barni; Irene Floriani; Stefano Cereda; R Berardi; Stefania Mosconi; Valter Torri; Roberto Labianca
Venous thromboembolism predicts poor prognosis in irresectable pancreatic cancer patients.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2007;18(10):1660-5.
2007: Mario Mandalà; Cecilia Moro; Roberto Labianca; Gianluigi Ferretti
Erlotinib in pancreatic cancer patients: do we need more information from the NCIC CTG trial?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(27):4320-1; author reply 4321-2.
2007: MARIO SCARTOZZI; Italo Bearzi; Chiara Pierantoni; Alessandra Mandolesi; Fotios Loupakis; alberto zaniboni; Vincenzo Catalano; Antonello Quadri; Fausto Zorzi; Rossana Berardi; Tommasina Biscotti; Roberto Labianca; Alfredo Falcone; Stefano Cascinu
Nuclear factor-kB tumor expression predicts response and survival in irinotecan-refractory metastatic colorectal cancer treated with cetuximab-irinotecan therapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(25):3930-5.
2007: Cornelis J A Punt; Marc Buyse; Claus-Henning Köhne; Peter Hohenberger; Roberto Labianca; Hans J Schmoll; Lars Påhlman; Alberto Sobrero; Jean-Yves Douillard
Endpoints in adjuvant treatment trials: a systematic review of the literature in colon cancer and proposed definitions for future trials.
Journal of the National Cancer Institute 2007;99(13):998-1003.
2007: mario mandala; Stefania Mosconi; Antonello Quadri; Laura Milesi; Roberto Labianca
Neoadjuvant chemotherapy for patients with liver metastases from colorectal cancer.
Expert review of anticancer therapy 2007;7(6):887-97.
2007: Florence Huguet; Thierry André; Pascal Hammel; Pascal Artru; Jacques Balosso; Frédéric Selle; Elisabeth Deniaud-Alexandre; Philippe Ruszniewski; Emmanuel Touboul; Roberto Labianca; Aimery de Gramont; Christophe Louvet
Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(3):326-31.
2007: Ermenegildo Arnoldi; Maria Dieli; Marina Mangia; Bruno Minetti; Roberto Labianca
Comprehensive geriatric assessment in elderly cancer patients: an experience in an outpatient population.
Tumori 2007;93(1):23-5.
2006: mario mandala; Cecilia Moro; Roberto Labianca; Marco Cremonesi; Sandro Barni
Optimizing use of opiates in the management of cancer pain.
Therapeutics and clinical risk management 2006;2(4):447-53.
2006: alain gelibter; Sara Lonardi; Susanna Di Segni; Andrea Fontana; Fotios Loupakis; Francesco Cognetti; Roberto Labianca
Are dose-finding studies still necessary when targeted therapy is associated with chemotherapy?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(28):4668-9; author reply 4669.
2006: MARIO SCARTOZZI; Alfredo Falcone; Francesca Pucci; Chiara Braconi; Chiara Pierantoni; Luigi Cavanna; Vittorio Franciosi; Rossana Berardi; Giordano D Beretta; Gianluca Masi; Giacomo Allegrini; alberto zaniboni; Roberto Labianca; Stefano Cascinu
Capecitabine and mitomycin C may be an effective treatment option for third-line chemotherapy in advanced colorectal cancer.
Tumori 2006;92(5):384-8.
2006: mario mandala; Anna Falanga; Andrea Piccioli; Paolo Prandoni; E M Pogliani; Roberto Labianca; Sandro Barni
Venous thromboembolism and cancer: guidelines of the Italian Association of Medical Oncology (AIOM).
Critical reviews in oncology/hematology 2006;59(3):194-204.
2006: Paola Mosconi; Cinzia Colombo; Roberto Labianca; Giovanni Apolone
Oncologists' opinions about research ethics committees in Italy: an update, 2004.
European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP) 2006;15(1):91-4.
2006: Marina E Cazzaniga; Luigi Dogliotti; Stefano Cascinu; Sandro Barni; Roberto Labianca; Silvana Chiara; Pier Franco Conte; Giampietro Gasparini; Lara Maria Pasetto; Valter Torri
Diagnosis, management and clinical outcome of bone metastases in breast cancer patients: results from a prospective, multicenter study.
Oncology 2006;71(5-6):374-81.
2006: Giovanni Apolone; Oscar Bertetto; Augusto Caraceni; Oscar Corli; Franco De Conno; Roberto Labianca; Marco Maltoni; Mariaflavia Nicora; Valter Torri; Furio Zucco
Pain in cancer. An outcome research project to evaluate the epidemiology, the quality and the effects of pain treatment in cancer patients.
Health and quality of life outcomes 2006;4():7.
2006: Cecilia Moro; Cinzia Brunelli; Guido Miccinesi; Mauro Fallai; Piero Morino; Massimo Piazza; Roberto Labianca; Carla Ripamonti
Edmonton symptom assessment scale: Italian validation in two palliative care settings.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2006;14(1):30-7.
2005: Daniel J Sargent; H Samuel Wieand; Daniel G Haller; Richard Gray; Jacqueline K Benedetti; Marc Buyse; Roberto Labianca; Jean Francois Seitz; Christopher J O'Callaghan; Guido Francini; Axel Grothey; Michael O'Connell; Paul J Catalano; Charles D Blanke; David Kerr; Erin Green; Norman Wolmark; Thierry Andre; Richard M Goldberg; Aimery de Gramont
Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(34):8664-70.
2005: Francesco Perrone; Maurizio Marangolo; Francesco Di Costanzo; Giuseppe Colucci; Lazzaro Repettos; Marco Merlano; Sabino De Placido; Valter Torri; Giuseppe Comella; Roberto Labianca; Valerio Parisi; Ciro Gallo
Cost of insurance policies for investigator-initiated cancer clinical trials in Italy.
Tumori 2005;91(4):373-9.
2005: Vincenzo Catalano; Roberto Labianca; Giordano D Beretta; Gemma Gatta; Filippo de Braud; Eric Van Cutsem
Gastric cancer.
Critical reviews in oncology/hematology 2005;54(3):209-41.
2005: Christophe Louvet; Roberto Labianca; P Hammel; Gérard Lledo; Maria Giulia Zampino; Thierry André; alberto zaniboni; M Ducreux; E Aitini; Julien Taïeb; R Faroux; C Lepere; Aimery de Gramont
Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(15):3509-16.
2005: Roberto Labianca; Giordano D Beretta; Stefania Mosconi; M Adelaide Pessi; Laura Milesi
The development of clinical research in CRC.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2005;16 Suppl 4():iv37-43.
2005: Cecilia Moro; Pierluigi Sironi; Eliana Berardi; Giordano Beretta; Roberto Labianca
Midazolam for long-term treatment of intractable hiccup.
Journal of pain and symptom management 2005;29(3):221-3.
2005: Filippo De Marinis; Fabrizio Nelli; Marco Lombardo; Francesco Ferraú; Santi Barbera; Oscar Bertetto; Sandro Barni; Giovanni Michetti; Roberto Labianca; Cesare Gridelli
A multicenter, randomized, Phase II study of cisplatin, etoposide, and gemcitabine or cisplatin plus gemcitabine as first-line treatment in patients with poor-prognosis small cell lung carcinoma.
Cancer 2005;103(4):772-9.
2005: MARIO SCARTOZZI; Alberto Sobrero; G Gasparini; Rossana Berardi; Vincenzo Catalano; Graziano Francesco; Sandro Barni; alberto zaniboni; Giordano D Beretta; Roberto Labianca; Stefano Cascinu
The role of 5-fluorouracil (5-FU) reintroduction with irinotecan or oxaliplatin in truly 5-FU-refractory advanced colorectal cancer patients.
Oncology 2005;68(2-3):212-6.
2005: Roberto Labianca; Giordano D Beretta; Stefania Mosconi; Laura Milesi; M Adelaide Pessi
Colorectal cancer: screening.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2005;16 Suppl 2():ii127-32.
2004: Alessandra Guglielmi; Sandro Barni; alberto zaniboni; N Pella; Ornella Belvedere; Giordano D Beretta; Francesco Grossi; Luciano Frontini; Fabio Puglisi; Roberto Labianca; Alberto Sobrero
Phase II study of a triplet regimen in advanced colorectal cancer using methotrexate, oxaliplatin and 5-fluorouracil.
British journal of cancer 2004;91(8):1428-33.
2004: Roberto Labianca; Giordano D Beretta; Stefania Mosconi; Laura Milesi
The role of uracil-tegafur (UFT) in elderly patients with colorectal cancer.
Critical reviews in oncology/hematology 2004;52(1):73-80.
2004: Giordano D Beretta; Laura Milesi; M Adelaide Pessi; Stefania Mosconi; Roberto Labianca
Adjuvant treatment of colorectal cancer.
Surgical oncology 2004;13(2-3):63-73.
2004: Roberto Labianca; Giordano Beretta; Gemma Gatta; Filippo de Braud; Jacques Wils
Colon cancer.
Critical reviews in oncology/hematology 2004;51(2):145-70.
2004: Maria Giulia Zampino; Roberto Labianca; Giordano Beretta; Gemma Gatta; Katia Lorrizo; Filippo de Braud Fd; Jacques Wils
Rectal cancer.
Critical reviews in oncology/hematology 2004;51(2):121-43.
2004: Roberto Labianca
[The AIOM (Italian Association of Medical Oncology) and clinical research].
I supplementi di Tumori : official journal of Società italiana di cancerologia ... [et al.] 2004;3(4):S41.
2004: Roberto Labianca; Roldano Fossati; alberto zaniboni; Valter Torri; Silvia Marsoni; Donato Nitti; Lamberto Boffi; Marco Scatizzi; Berardino Tardio; Nicola Mastrodonato; Stefano Banducci; Giampiero Consani; Gianfranco Pancera
Randomized trial of intraportal and/or systemic adjuvant chemotherapy in patients with colon carcinoma.
Journal of the National Cancer Institute 2004;96(10):750-8.
2004: Sharlene Gill; Charles L Loprinzi; Daniel J Sargent; Stephan D Thomé; Steven R Alberts; Daniel G Haller; Jacqueline K Benedetti; Guido Francini; Lois E Shepherd; Jean Francois Seitz; Roberto Labianca; Wei Chen; Stephen S Cha; Michael P Heldebrant; Richard M Goldberg
Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(10):1797-806.
2004: Raffaella Giavazzi; Massimo Aglietta; Annalisa Astolfi; Anna Falanga; Alfredo Fusco; Roberto Labianca; Pier-Luigi Lollini; Claudio Lombardo; Pier Giorgio Natali; Marco A Pierotti; Marco Presta; Massimo Santoro; Giulia Taraboletti; Gabriella Zupi; Giancarlo Vecchio
45th annual meeting of the Italian Cancer Society. Bergamo, 9-12 November 2003.
Tumori 2004;90(3):356-62.
2004: Stefano Cascinu; MARIO SCARTOZZI; Roberto Labianca; Vincenzo Catalano; Rosa Rita Silva; Sandro Barni; alberto zaniboni; A D'Angelo; Stefania Salvagni; Giancarlo Martignoni; Giordano D Beretta; Graziano Francesco; Rossana Berardi; Vittorio Franciosi
High curative resection rate with weekly cisplatin, 5-fluorouracil, epidoxorubicin, 6S-leucovorin, glutathione, and filgastrim in patients with locally advanced, unresectable gastric cancer: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD).
British journal of cancer 2004;90(8):1521-5.
2003: Graziano Francesco; Daniele Santini; Enrica Testa; Vincenzo Catalano; Giordano D Beretta; Stefania Mosconi; Giuseppe Tonini; Vittorio Lai; Roberto Labianca; Stefano Cascinu
A phase II study of weekly cisplatin, 6S-stereoisomer leucovorin and fluorouracil as first-line chemotherapy for elderly patients with advanced gastric cancer.
British journal of cancer 2003;89(8):1428-32.
2003: Luigi Manenti; Paola Paganoni; Irene Floriani; Fabio Landoni; Valter Torri; Alessandro Buda; Giulia Taraboletti; Roberto Labianca; Dorina Belotti; Raffaella Giavazzi
Expression levels of vascular endothelial growth factor, matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinases 1 and 2 in the plasma of patients with ovarian carcinoma.
European journal of cancer (Oxford, England : 1990) 2003;39(13):1948-56.
2003: Stefano Cascinu; Paolo Giordani; Romina Agostinelli; Giampietro Gasparini; Sandro Barni; Giordano D Beretta; Franca Pulita; Laura Iacorossi; Domenico Gattuso; Marzia Mare; Stefania Munaò; Roberto Labianca; Renata Todeschini; Roberta Camisa; Riccardo Cellerino; Giuseppe Catalano
Pain and its treatment in hospitalized patients with metastatic cancer.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2003;11(9):587-92.
2003: Vanna Chiarion-Sileni; Paola Del Bianco; Gian Luca De Salvo; G Lo Re; Antonella Romanini; Roberto Labianca; Rolando Nortilli; E Corgna; Maurizio Dalla Palma; G Lo Presti; Ruggero Ridolfi
Quality of life evaluation in a randomised trial of chemotherapy versus bio-chemotherapy in advanced melanoma patients.
European journal of cancer (Oxford, England : 1990) 2003;39(11):1577-85.
2003: Anna Cecilia Bettini; Giordano D Beretta; Pierluigi Sironi; Stefania Mosconi; Roberto Labianca
Chemotherapy in small bowel adenocarcinoma associated with celiac disease: a report of three cases.
Tumori 2003;89(2):193-5.
2003: Stefano Cascinu; Roberto Labianca; Vincenzo Catalano; Sandro Barni; Francesco Ferraù; Giordano D Beretta; Luciano Frontini; P Foa; Gianfranco Pancera; Domenico Priolo; Graziano Francesco; Marzia Mare; Giuseppe Catalano
Weekly gemcitabine and cisplatin chemotherapy: a well-tolerated but ineffective chemotherapeutic regimen in advanced pancreatic cancer patients. A report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD).
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003;14(2):205-8.
2003: Tommaso De Pas; Paolo G Casali; Salvatore Toma; Antonella Romanini; Bruno Massidda; Alessandro Comandone; Roberto Labianca; Christian Massacesi; Antonio Tucci; Mauro Antimi; Guido Biasco; Massimo Aglietta; Gaetano Apice; Filippo de Braud
Gastrointestinal stromal tumors: should they be treated with the same systemic chemotherapy as other soft tissue sarcomas?
Oncology 2003;64(2):186-8.
2002: Giordano D Beretta; Roberto Labianca
Individual tailored chemotherapy.
I supplementi di Tumori : official journal of Società italiana di cancerologia ... [et al.] 2002;1(6):S25-7.
2002: Stefano Cascinu; Vincenzo Catalano; Luigi Cordella; Roberto Labianca; Paolo Giordani; Anna Maria Baldelli; Giordano D Beretta; Emilio Ubiali; Giuseppe Catalano
Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomized, double-blind, placebo-controlled trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(16):3478-83.
2002: Stefano Cascinu; Graziano Francesco; Francesco Ferraù; Vincenzo Catalano; Cristian Massacesi; Daniele Santini; Rosa Rita Silva; Sandro Barni; alberto zaniboni; Nicola Battelli; S Siena; Paolo Giordani; Davide Mari; Anna Maria Baldelli; Stefania Antognoli; Roberto Maisano; Domenico Priolo; MA Pessi; Giuseppe Tonini; S Rota; Roberto Labianca
Raltitrexed plus oxaliplatin (TOMOX) as first-line chemotherapy for metastatic colorectal cancer. A phase II study of the Italian Group for the Study of Gastrointestinal Tract Carcinomas (GISCAD).
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2002;13(5):716-20.
2002: Ruggero Ridolfi; Vanna Chiarion-Sileni; Michele Guida; Antonella Romanini; Roberto Labianca; Andrea Freschi; Giovanni Lo Re; Rolando Nortilli; Sonia Brugnara; Patrizia Vitali; Oriana Nanni
Cisplatin, dacarbazine with or without subcutaneous interleukin-2, and interferon alpha-2b in advanced melanoma outpatients: results from an Italian multicenter phase III randomized clinical trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(6):1600-7.
2002: Paola Poletti; Graziella Pinotti; Gerardo Rosati; Gabriele Luppi; Toni Ibrahim; Claudio Marinozzi; Francesca Pucci; Gianfranco Pancera; Guido Biasco; Sandro Barni; Carlo Garufi; Giancarlo Martignoni; Giovanni Visonà; Roberto Labianca
"Misura" project: a retrospective survey on the use of 5fluorouracil in the treatment of colorectal cancer in 24 Italian clinical centers.
Tumori 2002;88(2):104-9.
2002: Stefano Cascinu; Anna Maria Baldelli; Vincenzo Catalano; Paolo Giordani; Giordano D Beretta; Rosa Rita Silva; G Gasparini; Davide Mari; Roberto Maisano; Stefania Salvagni; Sandro Barni; Roberto Labianca; Luciano Frontini; C Curti; Giuseppe Catalano
Infusional 5-fluorouracil, cisplatin and mitomycin C in advanced gastric cancer: a low cost effective regimen.
British journal of cancer 2002;86(2):213-7.
2002: Roberto Labianca; Giordano D Beretta; Stefania Mosconi; M Adelaide Pessi
Is there an advantage for oral therapy in elderly? UFT.
Tumori 2002;88(1 Suppl 1):S71-2.
2002: Giordano D Beretta; Vittorio D Ferrari; Sandro Barni; Gianfranco Pancera; Roberto Labianca
Medical treatment of colorectal cancer in elderly (>70 years): GISCAD experience and future perspectives. Italian Group for the Study of Digestive Tract Cancer.
Tumori 2002;88(1 Suppl 1):S109-12.
2001: Daniel J Sargent; Richard M Goldberg; S D Jacobson; J S Macdonald; Roberto Labianca; Daniel G Haller; L E Shepherd; J F Seitz; Guido Francini
A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients.
The New England journal of medicine 2001;345(15):1091-7.
2001: Paola Poletti; Giordano D Beretta; Stefania Mosconi; M Adelaide Pessi; Roberto Labianca
[Irinotecan and fluorouracil in combination in colorectal carcinoma: a little clarity].
Tumori 2001;87(5):A14-7.
2001: Giordano D Beretta; M Adelaide Pessi; Paola Poletti; Stefania Mosconi; Roberto Labianca
New drugs and combinations in the palliative treatment of colon and rectal cancer.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 2001;27(6):595-600.
2001: Alberto Sobrero; Alessandra Guglielmi; M Cirillo; E Recaldin; Giovanni Luca Frassineti; Carlo Aschele; Alberto Ravaioli; P Testore; Cinzia Caroti; Luigi Gallo; MA Pessi; Enrico Cortesi; Daniele Turci; Francesco Grossi; Roberto Labianca
5-fluorouracil modulated by leucovorin, methotrexate and mitomycin: highly effective, low-cost chemotherapy for advanced colorectal cancer.
British journal of cancer 2001;84(8):1023-8.
2001: Stefano Cascinu; Graziano Francesco; Sandro Barni; Roberto Labianca; Giuseppe Comella; Rossana Casaretti; Luciano Frontini; Vincenzo Catalano; Anna Maria Baldelli; Giuseppe Catalano
A phase II study of sequential chemotherapy with docetaxel after the weekly PELF regimen in advanced gastric cancer. A report from the Italian group for the study of digestive tract cancer.
British journal of cancer 2001;84(4):470-4.
2001: Roberto Labianca; Giordano D Beretta; M Adelaide Pessi
Disease management considerations: disease management considerations.
Drugs 2001;61(12):1751-64.
2000: Stefania Mosconi; Stefano Cascinu; alberto zaniboni; Vincenzo Catalano; Paolo Giordani; Giordano D Beretta; Giancarlo Martignoni; Gianfranco Pancera; Anna Maria Baldelli; Paola Poletti; C Curti; Roberto Labianca
The value of oxaliplatin in combination with continuous infusion +/- bolus 5-fluorouracil and levo-folinic acid in metastatic colorectal cancer progressing after 5FU-based chemotherapy: a GISCAD (Italian Group for the Study of Digestive Tract) cancer phase II trial.
Tumori 2000;86(6):465-9.
2000: Alberto Sobrero; alberto zaniboni; Giovanni Luca Frassineti; Carlo Aschele; Alessandra Guglielmi; Rosa Giuliani; Alberto Ravaioli; C Lanfranco; Cinzia Caroti; E Arnoldi; Sandro Barni; Luigi Gallo; MA Pessi; Daniele Turci; Enrico Cortesi; Francesco Grossi; Luciano Frontini; Elena Piazza; Paolo Bruzzi; Roberto Labianca
Schedule specific biochemical modulation of 5-fluorouracil in advanced colorectal cancer: a randomized study. GISCAD, IOR and collaborating centers.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2000;11(11):1413-20.
2000: Stefano Cascinu; Luciano Frontini; Roberto Labianca; Vincenzo Catalano; Sandro Barni; claudio graiff; G Picone; E Farinati; S Zonato; MA Pessi; C Curti; Giuseppe Catalano
A combination of a fixed dose rate infusion of gemcitabine associated to a bolus 5-fluorouracil in advanced pancreatic cancer, a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD).
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2000;11(10):1309-11.
2000: Giordano D Beretta; G Michetti; M O Belometti; G Gritti; A Quadri; Paola Poletti; Roberto Labianca
Gemcitabine plus vinorelbine in elderly or unfit patients with non-small cell lung cancer.
British journal of cancer 2000;83(5):573-6.
2000: Roberto Labianca; Giordano D Beretta; M Adelaide Pessi; Paola Poletti
[Adjuvant chemotherapy in colon cancer: certainties and questions] .
Tumori 2000;86(4):A1-3.
2000: E Mari; Irene Floriani; Angelo Tinazzi; Alessandro Buda; Maurizio Belfiglio; Miriam Valentini; S Cascinu; S Barni; Roberto Labianca; Valter Torri
Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: a meta-analysis of published randomised trials. A study of the GISCAD (Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente).
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2000;11(7):837-43.
1999: R Grilli; R Trisolini; Roberto Labianca; P Zola
Evolution of physicians' attitudes towards practice guidelines.
Journal of health services research & policy 1999;4(4):215-9.
1999: Stefano Cascinu; Rosa Rita Silva; Roberto Labianca; Sandro Barni; Rodolfo Mattioli; Giancarlo Martignoni; Luciano Frontini; Giampietro Gasparini; Vincenzo Catalano; Anna Maria Baldelli; Luciano Giuliodori; Romina Agostinelli; Giuseppe Catalano
A phase II study of Tomudex alternated with methotrexate, 5-fluorouracil, leucovorin in first-line chemotherapy of metastatic colorectal cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1999;10(8):985-7.
1999: Stefano Cascinu; Rosa Rita Silva; Sandro Barni; Roberto Labianca; Luciano Frontini; Elena Piazza; Gianfranco Pancera; Paolo Giordani; Luciano Giuliodori; MA Pessi; V Fusco; G Luporini; Riccardo Cellerino; Giuseppe Catalano
A combination of gemcitabine and 5-fluorouracil in advanced pancreatic cancer, a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD).
British journal of cancer 1999;80(10):1595-8.
1999: Sandro Barni; Stefano Cascinu; P Foa; Luciano Frontini; Roberto Labianca; G Luporini; Mario Mandalà; Giancarlo Martignoni; Gianfranco Pancera; Alberto Sobrero; alberto zaniboni
[Adjuvant therapy of colon cancer. State of the art and future perspectives].
Tumori 1999;85(3):A1-6.
1999: Rodolfo Passalacqua; F Campione; Caterina Caminiti; Stefania Salvagni; A Barilli; Maria A Bella; S Barni; G Barsanti; O Caffo; Paolo Carlini; G Cinquemani; Francesco Di Costanzo; Lucio Giustini; Roberto Labianca; A Mazzei; N Olmeo; A Paccagnella; L Toscano; Giorgio Cocconi
Patients' opinions, feelings, and attitudes after a campaign to promote the Di Bella therapy.
Lancet 1999;353(9161):1310-4.
1999: Marco Maltoni; Oriana Nanni; M Pirovano; Emanuela Scarpi; M Indelli; Cinzia Martini; M Monti; E Arnoldi; L Piva; Alberto Ravaioli; G Cruciani; Roberto Labianca; Dino Amadori
Successful validation of the palliative prognostic score in terminally ill cancer patients. Italian Multicenter Study Group on Palliative Care.
Journal of pain and symptom management 1999;17(4):240-7.
1999: M Pirovano; Marco Maltoni; Oriana Nanni; M Marinari; M Indelli; G Zaninetta; V Petrella; Sandro Barni; Ernesto Zecca; Emanuela Scarpi; Roberto Labianca; Dino Amadori; G Luporini
A new palliative prognostic score: a first step for the staging of terminally ill cancer patients. Italian Multicenter and Study Group on Palliative Care.
Journal of pain and symptom management 1999;17(4):231-9.
1999: Stefano Cascinu; Luciano Frontini; Giuseppe Comella; Sandro Barni; Roberto Labianca; Nicola Battelli; Rossana Casaretti; S Zonato; M Pirovano; Giuseppe Catalano; Riccardo Cellerino
Intensive weekly chemotherapy is not effective in advanced pancreatic cancer patients: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD).
British journal of cancer 1999;79(3-4):491-4.
1999: R Grilli; R Trisolini; Roberto Labianca; P Zola
[How have opinions of medical oncologists changed regarding compared guidelines? Findings from two surveys conducted in 1993-1997].
Epidemiologia e prevenzione 1999;23(1):47-51.
1999: M C Locatelli; G Facendola; Giorgio Pizzocaro; Luigi Piva; C Pegoraro; E B Pallavicini; A Signaroldi; M Meregalli; F Lombardi; G D Beretta; F Scanzi; Roberto Labianca; G Dallavalle; G Luporini
Subcutaneous administration of interleukin-2 and interferon-alpha 2b in advanced renal cell carcinoma: long-term results.
Cancer detection and prevention 1999;23(2):172-6.
1998: Roberto Labianca; Paola Poletti
[5-fluorouracil and colorectal tumors: use in clinical practice and the "MISURA" project].
Tumori 1998;84(6 Suppl 2):S10-2.
1998: Stefano Cascinu; Roberto Labianca; Graziano Francesco; Gianfranco Pancera; Sandro Barni; Luciano Frontini; G Luporini; Riccardo Cellerino; Giuseppe Catalano
Intensive weekly chemotherapy for locally advanced gastric cancer using 5-fluorouracil, cisplatin, epidoxorubicin, 6S-leucovorin, glutathione and filgrastim: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD).
British journal of cancer 1998;78(3):390-3.
1998: P Rougier; TM Sahmoud; D Nitti; Desmond Curran; R Doci; B De Waele; T Nakajima; H Rauschecker; Roberto Labianca; J C Pector; Silvia Marsoni; giovanni Apolone; P Lasser; ML Couvreur; J Wils
Adjuvant portal-vein infusion of fluorouracil and heparin in colorectal cancer: a randomised trial. European Organisation for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group, the Gruppo Interdisciplinare Valutazione Interventi in Oncologia, and the Japanese Foundation for Cancer Research.
Lancet 1998;351(9117):1677-81.
1998: alberto zaniboni; Roberto Labianca; Silvia Marsoni; Valter Torri; Paola Mosconi; R Grilli; giovanni Apolone; S Cifani; Angelo Tinazzi
GIVIO-SITAC 01: A randomized trial of adjuvant 5-fluorouracil and folinic acid administered to patients with colon carcinoma--long term results and evaluation of the indicators of health-related quality of life. Gruppo Italiano Valutazione Interventi in Oncologia. Studio Italiano Terapia Adiuvante Colon.
Cancer 1998;82(11):2135-44.
1998: Jacques A Wils; TM Sahmoud; A Sobrero; Harry Bleiberg; S Ahmedzai; J Blazeby; Geert H Blijham; T Conroy; D Cunningham; Desmond Curran; E Díaz-Rubio; M Ducreux; J Evans; B Glimelius; G Hutchinson; D Kerr; GM Kiebert; H Köhne; Roberto Labianca; R Langendijk; Donato Nitti; B Nordlinger; P Rougier; W Scheithauer; P Therasse
Evaluation of clinical efficacy of new medical treatments in advanced colorectal cancer. Results of a workshop organized by the EORTC GITCCG. European Organization for Research and Treatment of Cancer. Gastrointestinal Tract Cancer Cooperative Group.
Tumori 1998;84(3):335-47.
1998: R Grilli; S Minozzi; Angelo Tinazzi; Roberto Labianca; Trevor Sheldon; Alessandro Liberati
Do specialists do it better? The impact of specialization on the processes and outcomes of care for cancer patients.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1998;9(4):365-74.
1998: Eduardo Díaz-Rubio; Javier Sastre; alberto zaniboni; Roberto Labianca; Hernán Cortés-Funes; F de Braud; C Boni; M Benavides; G Dallavalle; M Homerin
Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: a phase II multicentric study.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1998;9(1):105-8.
1998: Carlo Aschele; Alessandra Guglielmi; Giovanni Luca Frassineti; Carlo Milandri; Dino Amadori; Roberto Labianca; M Vinci; L Tixi; Cinzia Caroti; E Ciferri; E Verdi; Riccardo Rosso; Alberto Sobrero
Schedule-selective biochemical modulation of 5-fluorouracil in advanced colorectal cancer: a multicentric phase II study.
British journal of cancer 1998;77(2):341-6.
1997: Stefano Cascinu; Roberto Labianca; Paolo Alessandroni; M Marcellini; Rosa Rita Silva; Gianfranco Pancera; Enrica Testa; Giancarlo Martignoni; Sandro Barni; Luciano Frontini; alberto zaniboni; G Luporini; Riccardo Cellerino; Giuseppe Catalano
Intensive weekly chemotherapy for advanced gastric cancer using fluorouracil, cisplatin, epi-doxorubicin, 6S-leucovorin, glutathione, and filgrastim: a report from the Italian Group for the Study of Digestive Tract Cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(11):3313-9.
1997: Stefano Cascinu; Sandro Barni; Roberto Labianca; E Del Ferro; Marco Rocchi; M Ligi; MA Pessi; Marina Cazzaniga; G Zamparelli; A Ardizzoia; G Ugolini; G Ghiandoni; G Luporini; Giuseppe Catalano
Evaluation of factors influencing 5-fluorouracil-induced diarrhea in colorectal cancer patients. An Italian Group for the Study of Digestive Tract Cancer (GISCAD) study.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 1997;5(4):314-7.
1997: Roberto Labianca; MA Pessi; G Zamparelli
Treatment of colorectal cancer. Current guidelines and future prospects for drug therapy.
Drugs 1997;53(4):593-607.
1997: Roberto Labianca; Stefano Cascinu; Luciano Frontini; Sandro Barni; Giammaria Fiorentini; Giuseppe Comella; alberto zaniboni; O Gottardi; E Arnoldi; Cristina Oliani; Maria Duro; G Pavanato; Giancarlo Martignoni; A Raina; Elena Piazza; G Dallavalle; R Valsecchi; Gianfranco Pancera; G Luporini
High-versus low-dose levo-leucovorin as a modulator of 5-fluorouracil in advanced colorectal cancer: a 'GISCAD' phase III study. Italian Group for the Study of Digestive Tract Cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1997;8(2):169-74.
1997: Roberto Labianca; Gianfranco Pancera; G Dallavalle; A Pessi; G Zamparelli
Response evaluation as the key-point in results interpretation.
Tumori 1997;83(1 Suppl):S73-6.
1997: Marco Maltoni; M Pirovano; Oriana Nanni; M Marinari; M Indelli; A Gramazio; E Terzoli; M Luzzani; F De Marinis; Augusto Caraceni; Roberto Labianca
Biological indices predictive of survival in 519 Italian terminally ill cancer patients. Italian Multicenter Study Group on Palliative Care.
Journal of pain and symptom management 1997;13(1):1-9.
1996: G Zamparelli; Gianfranco Pancera; MA Pessi; G Dallavalle; M Pirovano; R Valsecchi; Roberto Labianca; G Samori; G Luporini
[Locoregional chemotherapy of liver metastasis from colorectal carcinoma].
Annali italiani di chirurgia 1996;67(6):793-7.
1996: Roberto Labianca; Gianfranco Pancera; G Luporini
Factors influencing response rates for advanced colorectal cancer chemotherapy.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1996;7(9):901-6.
1996: M C Locatelli; L Tedeschi; M Clerici; A Romanelli; A D'Antona; Roberto Labianca; G Luporini
Cisplatin-associated anaemia in patients with solid tumours. A retrospective evaluation and considerations relative to erythropoietin administration.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 1996;4(3):218-9.
1996: alberto zaniboni; Roberto Labianca; Giancarlo Martignoni; Sandro Barni; M Vinci; M Vaghi; M Pirovano; G Facendola; G Marini; G Luporini
Sequential methotrexate and 5-fluorouracil as second-line chemotherapy for advanced colorectal cancer patients pretreated with 5-fluorouracil and leucovorin: a GISCAD study.
Journal of chemotherapy (Florence, Italy) 1996;8(1):82-4.
1996: Roberto Labianca; A Pessi; G Facendola; M Pirovano; G Luporini
Modulated 5-fluorouracil (5-FU) regimens in advanced colorectal cancer: a critical review of comparative studies.
European journal of cancer (Oxford, England : 1990) 1996;32A Suppl 5():S7-12.
1995: alberto zaniboni; Sandro Barni; Roberto Labianca; G Marini; Gianfranco Pancera; G Giaccon; Elena Piazza; A Signaroldi; W Legnani; G Luporini
Epirubicin, cisplatin, and continuous infusion 5-fluorouracil is an active and safe regimen for patients with advanced gastric cancer. An Italian Group for the Study of Digestive Tract Cancer (GISCAD) report.
Cancer 1995;76(10):1694-9.
1995: Mario Lise; Donato Nitti; Alberto Marchet; TM Sahmoud; N Duez; A Fornasiero; J G dos Santos; Roberto Labianca; P Lasser; M Gignoux
Prognostic factors in resectable gastric cancer: results of EORTC study no. 40813 on FAM adjuvant chemotherapy.
Annals of surgical oncology 1995;2(6):495-501.
1995: Mario Lise; Donato Nitti; Alberto Marchet; TM Sahmoud; Marc Buyse; N Duez; M Fiorentino; J G Dos Santos; Roberto Labianca; P Rougier
Final results of a phase III clinical trial of adjuvant chemotherapy with the modified fluorouracil, doxorubicin, and mitomycin regimen in resectable gastric cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(11):2757-63.
1995: alberto zaniboni; Roberto Labianca; Gianfranco Pancera; Sandro Barni; Luciano Frontini; G Marini; G Luporini
Oral etoposide as second-line chemotherapy for colorectal cancer: a GISCAD study. Gruppo Italiano Studio Carcinomi Apparato Digerente.
Journal of chemotherapy (Florence, Italy) 1995;7(3):246-8.
1994: L Brambilla; Roberto Labianca; Vinicio Boneschi; S Fossati; G Dallavalle; A F Finzi; G Luporini
Mediterranean Kaposi's sarcoma in the elderly. A randomized study of oral etoposide versus vinblastine.
Cancer 1994;74(10):2873-8.
1994: L Tedeschi; A Romanelli; G Dallavalle; E Tavani; E Arnoldi; M Vinci; G Mortara; P Bedoni; Roberto Labianca; G Luporini
Stages I and II non-Hodgkin's lymphoma of the gastrointestinal tract. Retrospective analysis of 79 patients and review of the literature.
Journal of clinical gastroenterology 1994;18(2):99-104.
1994: R Rosso; T Mazzei; A Sobrero; Enrico Mini; Giuseppe Cartei; PierFranco Conte; Roberto Labianca; Francesco Cartei; Alfredo Falcone; Gianfranco Pancera
Phase II trial of 5-fluorouracil and the natural l isomer of folinic acid in the treatment of advanced colorectal carcinoma.
European journal of cancer (Oxford, England : 1990) 1994;30A(3):338-43.
1994: Roberto Labianca; G Giaccon; Sandro Barni; G Ambrosini; A Iirillo; G Fiorentini; M Duro; Elena Piazza; C Oliani; Gianfranco Pancera
Double modulation of 5-fluorouracil in advanced colorectal cancer with low-dose interferon-alpha 2b and folinic acid. The "GISCAD" experience. Italian Group for the Study of Digestive Tract Cancer.
European journal of cancer (Oxford, England : 1990) 1994;30A(11):1611-6.
1993: M C Locatelli; A D'Antona; R Carcione; B Cesana; G Dallavalle; M Vinci; M Clerici; Roberto Labianca; C Pasquinucci; G Luporini
A cisplatinum-cyclophosphamide regimen in advanced ovarian cancer: reporting 5-year results.
Oncology 1993;50(2):92-9.
1993: M C Locatelli; A D'Antona; Roberto Labianca; M Vinci; M Tedeschi; R Carcione; A Corbo; P Venturino; G Luporini
A phase II study of combination chemotherapy in advanced ovarian carcinoma with cisplatin and cyclophosphamide plus reduced glutathione as potential protective agent against cisplatin toxicity.
Tumori 1993;79(1):37-9.
1993: G Luporini; Roberto Labianca; Gianfranco Pancera
Medical treatment of hepatocellular carcinoma.
Journal of surgical oncology. Supplement 1993;3():115-8.
1993: Roberto Labianca; Gianfranco Pancera; Sandro Barni; Stefano Cascinu; Giuseppe Comella; P Foa; Giancarlo Martignoni; alberto zaniboni; G Giaccon; G Luporini
Biochemical modulation of fluoropyrimidines: the "GISCAD" studies. GISCAD (Italian Group for the Study of Digestive Tract Cancer).
Advances in experimental medicine and biology 1993;339():233-7.
1992: Roberto Labianca; Gianfranco Pancera; L Tedeschi; G Dallavalle; A Luporini; G Luporini
High dose alpha-2b interferon + folinic acid in the modulation of 5-fluorouracil. A phase II study in advanced colorectal cancer with evidence of an unfavourable cost/benefit ratio.
Tumori 1992;78(1):32-4.
1991: Roberto Labianca; Gianfranco Pancera; E Aitini; S Barni; A Beretta; G D Beretta; B Cesana; Giuseppe Comella; L Cozzaglio; M Cristoni
Folinic acid + 5-fluorouracil (5-FU) versus equidose 5-FU in advanced colorectal cancer. Phase III study of 'GISCAD' (Italian Group for the Study of Digestive Tract Cancer).
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1991;2(9):673-9.
1991: Silvia Marsoni; Valter Torri; A Taiana; A Liberati; Roberto Labianca; Gianfranco Pancera; R Gray; M Clarke
Efficacy of intraportal infusion for colon cancer: a fair assessment?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1991;9(5):888-9.
1991: Roberto Labianca; G Luporini
5-fluorouracil cardiotoxicity: the risk of rechallenge.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1991;2(5):383.
1991: G Luporini; Roberto Labianca; Gianfranco Pancera
Chemotherapy for patients not benefitting from 5-fluorouracil therapy.
Journal of surgical oncology. Supplement 1991;2():161-4.
1990: Giovanni Apolone; R Grilli; A A Alexanian; C Confalonieri; Roberto Labianca; P Liati; Silvia Marsoni; Giancarlo Martignoni; Paola Mosconi; A Nicoluci
Quality of care of colorectal cancer patients in general hospitals: diffusion and impact of management guidelines.
Tumori 1990;76(3):261-9.
1988: Roberto Labianca; Gianfranco Pancera; B Cesana; M Clerici; F Montinari; G Luporini
Cisplatin + 5-fluorouracil versus 5-fluorouracil alone in advanced colorectal cancer: a randomized study.
European journal of cancer & clinical oncology 1988;24(10):1579-81.
1987: G Segalini; Roberto Labianca; G D Beretta; E Borsotti; F Calasso; L Carini; S De Ceglia; A Rocca
[Cardiotoxicity of 5-fluorouracil. Personal cases and review of the literature].
Giornale italiano di cardiologia 1987;17(9):781-5.
1987: G Beretta; C Locatelli; D Tabiadon; Roberto Labianca; P Fraschini; G Luporini
Epirubicin treatment of advanced breast carcinoma with the weekly low-dose regimen.
Oncology 1987;44(1):6-12.
1983: P Fraschini; G Beretta; E Arnoldi; L Tedeschi; Roberto Labianca; G Luporini
Confirmed activity of FAM polychemotherapy in advanced gastric carcinoma.
Tumori 1983;69(1):59-64.
1982: Roberto Labianca; G Beretta; M Clerici; P Fraschini; G Luporini
Cardiac toxicity of 5-fluorouracil: a study on 1083 patients.
Tumori 1982;68(6):505-10.